Literature DB >> 17256744

Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins.

Martin Hennenberg1, Jonel Trebicka, Erwin Biecker, Michael Schepke, Tilman Sauerbruch, Jörg Heller.   

Abstract

UNLABELLED: In cirrhosis, vascular hypocontractility leads to vasodilation and contributes to portal hypertension. Impaired activation of contractile pathways contributes to vascular hypocontractility. Angiotensin II type 1 receptors (AT1-Rs) are coupled to the contraction-mediating RhoA/Rho-kinase pathway and may be desensitized by phosphorylation through G-protein-coupled receptor kinases (GRKs) and binding of beta-arrestin-2. In the present study, we analyzed vascular hypocontractility to angiotensin II in cirrhosis. Human hepatic arteries were obtained during liver transplantation. In rats, cirrhosis was induced by bile duct ligation (BDL). Contractility of rat aortic rings was measured myographically. Protein expression and phosphorylation were analyzed by Western blot analysis. Immunoprecipitation was performed with protein A-coupled Sepharose beads. Myosin light chain (MLC) phosphatase activity was assessed as dephosphorylation of MLCs. Aortas from BDL rats were hyporeactive to angiotensin II and extracellular Ca2+. Expression of AT1-R and Galphaq/11,12,13 remained unchanged in hypocontractile rat and human vessels, whereas GRK-2 and beta-arrestin-2 were up-regulated. The binding of beta-arrestin-2 to the AT1-R was increased in hypocontractile rat and human vessels. Inhibition of angiotensin II-induced aortic contraction by the Rho-kinase inhibitor Y-27632 was pronounced in BDL rats. Basal phosphorylation of the ROK-2 substrate moesin was reduced in vessels from rats and patients with cirrhosis. Analysis of the expression and phosphorylation of Ca(2+)-sensitizing proteins (MYPT1 and CPI-17) in vessels from rats and patients with cirrhosis suggested decreased Ca2+ sensitivity. Angiotensin II-stimulated moesin phosphorylation was decreased in aortas from BDL rats. MLC phosphatase activity was elevated in aortas from BDL rats.
CONCLUSION: Vascular hypocontractility to angiotensin II in cirrhosis does not result from changes in expression of AT1-Rs or G-proteins. Our data suggest that in cirrhosis-induced vasodilation, the AT1-R is desensitized by GRK-2 and beta-arrestin-2 and that changed patterns of phosphorylated Ca(2+) sensitizing proteins decrease Ca(2+) sensitivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17256744     DOI: 10.1002/hep.21502

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

2.  Morphological and biomechanical remodelling of the hepatic artery in a swine model of portal hypertension.

Authors:  Xi-Ju He; Ming-Hua Yu; Wen-Chun Li; Han-Qin Wang; Jing Li; Xing-Chun Peng; Jie Tang; Na Feng; Tie-Zhu Huang
Journal:  Hepatol Int       Date:  2011-09-23       Impact factor: 6.047

3.  β-arrestin-2 is expressed in human prostate smooth muscle and a binding partner of α1A-adrenoceptors.

Authors:  Martin Hennenberg; Boris Schlenker; Alexander Roosen; Frank Strittmatter; Sebastian Walther; Christian Stief; Christian Gratzke
Journal:  World J Urol       Date:  2011-01-22       Impact factor: 4.226

4.  Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats.

Authors:  Qing-Hong Du; Lin Han; Jun-Jie Jiang; Ya Xu; Wei-Hong Li; Peng-Tao Li; Xin-Yue Wang; Xu Jia
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

5.  Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats.

Authors:  Qing-Hong Du; Lin Han; Jun-Jie Jiang; Peng-Tao Li; Xin-Yue Wang; Xu Jia
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

6.  Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

Authors:  Chandana B Herath; Josephine A Grace; Peter W Angus
Journal:  World J Gastrointest Pathophysiol       Date:  2013-02-15

Review 7.  β-Arrestins in the immune system.

Authors:  Dianhua Jiang; Ting Xie; Jiurong Liang; Paul W Noble
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

8.  Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.

Authors:  M Hennenberg; J Trebicka; C Stark; A Z Kohistani; J Heller; T Sauerbruch
Journal:  Br J Pharmacol       Date:  2009-03-26       Impact factor: 8.739

9.  Estrogen improves the hyperdynamic circulation and hyporeactivity of mesenteric arteries by alleviating oxidative stress in partial portal vein ligated rats.

Authors:  Bin Zhang; Cheng-Gang Zhang; Quan-Bo Zhou; Wei Chen; Zhi-Yong Wu
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

Review 10.  Beta-Arrestins in the Treatment of Heart Failure Related to Hypertension: A Comprehensive Review.

Authors:  Ahmed Rakib; Taslima Akter Eva; Saad Ahmed Sami; Saikat Mitra; Iqbal Hossain Nafiz; Ayan Das; Abu Montakim Tareq; Firzan Nainu; Kuldeep Dhama; Talha Bin Emran; Jesus Simal-Gandara
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.